Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash & Equivalents (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Cash & Equivalents for 4 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 24.69% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 24.69% increase, with the full-year FY2024 number at $1.7 million, down 22.55% from a year prior.
  • Cash & Equivalents was $4.1 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $2.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.1 million in Q3 2025 to a low of $19070.0 in Q2 2023.
  • A 4-year average of $1.8 million and a median of $1.8 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 97.46% in 2023, then skyrocketed 9551.25% in 2024.
  • 60 Degrees Pharmaceuticals' Cash & Equivalents stood at $264865.0 in 2022, then skyrocketed by 708.9% to $2.1 million in 2023, then decreased by 22.55% to $1.7 million in 2024, then surged by 148.04% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Cash & Equivalents are $4.1 million (Q3 2025), $2.0 million (Q2 2025), and $3.5 million (Q1 2025).